Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-1.22% $6.46
America/New_York / 24 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 497.25 mill |
EPS: | -0.130 |
P/E: | -49.69 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 231.77 mill |
Avg Daily Volume: | 2.53 mill |
RATING 2024-04-24 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -49.69 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-8.45x |
Company: PE -49.69 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 6.24 - 6.68 ( +/- 3.42%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Kestenberg-messina Kaitlin M. | Buy | 192 320 | Common Stock |
2024-04-01 | Kestenberg-messina Kaitlin M. | Buy | 300 328 | Stock Option (right to buy) |
2024-03-31 | Kestenberg-messina Kaitlin M. | Sell | 2 085 | Common Stock |
2024-03-31 | Grossman Adam S | Sell | 21 752 | Common Stock |
2024-04-01 | Kestenberg-messina Kaitlin M. | Sell | 0 | Common Stock |
INSIDER POWER |
---|
-15.53 |
Last 100 transactions |
Buy: 7 559 578 | Sell: 9 852 560 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $6.46 (-1.22% ) |
Volume | 1.663 mill |
Avg. Vol. | 2.53 mill |
% of Avg. Vol | 65.76 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $5.14 | N/A | Active |
---|
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.